Company Performance Metrics
Kyrexa develops veterinary oncology therapeutics for the treatment of cancer in companion animals, with a focus on canine patients. The company applies principles of comparative oncology to leverage molecular and therapeutic similarities between human and canine malignancies. Its research centers on tumor microenvironments and cellular responses to
create targeted small-molecule therapies. Kyrexa designs treatments that aim to maintain quality of life and minimize the side effects associated with traditional chemotherapy. Its lead candidates are intended to be administered by pet owners, enabling treatment outside clinical settings. The company advances a development pipeline of novel veterinary drugs toward regulatory milestones and future use in veterinary practice.
